Mircea Popescu - Plainsboro NJ, US Lawrence Boni - Monmouth Junction NJ, US Richard Robb - Princeton Junction NJ, US Michael Batenjany - Hamilton NJ, US
International Classification:
A61K039/00 A61K009/127
US Classification:
424/277100, 424/450000
Abstract:
Membrane-proteoliposome structures (MPs) are useful in preparing patient-specific vaccines against specific white blood cell (WBC) malignancies. The inventive MPs typically contain a membrane component derived from a specific WBC. Other useful components include immunostimulators and exogenous lipids. The resulting vaccines are both patient- and malignancy-specific.
Lawrence Boni - Monmouth Junction NJ, US Michael Batenjany - Hamilton NJ, US Richard Robb - Princeton Junction NJ, US Mircea Popescu - Plansboro NJ, US Mary Neville - Jamesburg NJ, US
International Classification:
A61K009/127 A61K038/19 A61K038/20 A61K031/739
US Classification:
424/450000, 424/085100, 424/085200, 514/054000
Abstract:
The invention describes a Lipomatrix composed of lipid lattices of stacked bilayers which, when hydrated, form liposomes. The invention also provides a simplified method used to generate highly effective liposomal preparations. Vaccine compositions having superior immunological properties use biomedical-grade liposomes which can be produced from a Lipomatrix, using safe and efficient methods. Use of the inventive methods produces highly potent vaccines against tumor antigens.
Method Of Making Patient-Specific White Blood Cell Malignancy Vaccine From Membrane-Proteoliposomes
Mircea Popescu - Plansboro NJ, US Lawrence Boni - Monmouth Junction NJ, US Richard Robb - Princeton Junction NJ, US Michael Batenjany - Hamilton NJ, US
Assignee:
BIOMIRA U.S.A., Inc.
International Classification:
A61K039/00 C12N005/08
US Classification:
424/277100, 435/372000
Abstract:
Membrane-proteoliposome structures (MPs) are useful in preparing patient-specific vaccines against specific white blood cell (WBC) malignancies. The inventive MPs typically contain a membrane component derived from a specific WBC. Other useful components include immunostimulators and exogenous lipids. The resulting vaccines are both patient- and malignancy-specific.
Patient-Specific White Blood Cell Malignancy Vaccine From Membrane-Proteoliposomes
Mircea C. Popescu - Plansboro NJ Lawrence Boni - Monmouth Junction NJ Richard J. Robb - Princeton Junction NJ Michael M. Batenjany - Hamilton NJ
Assignee:
Biomira U.S.A., Inc. - Cranbury NJ
International Classification:
A61K39/00;39/385;39/39;47/00;47/02
US Classification:
4242771
Abstract:
Membrane-proteoliposome structures (MPs) are useful in preparing patient-specific vaccines against specific white blood cell (WBC) malignancies. The inventive MPs typically contain a membrane component derived from a specific WBC. Other useful components include immunostimulators and exogenous lipids. The resulting vaccines are both patient- and malignancy-specific.
Name / Title
Company / Classification
Phones & Addresses
Richard Robb Vice-President
Xeme Biopharma Inc Commercial Physical Research · Mfg Pharmaceutical Preparations
Richard Robb (1981-1985), Tammy Lyons (1976-1980), Charlie Clark (1974-1978), Regina Clark (1980-1984), Lori Brockmeyer (1985-1989), Sandra Fedderke (1975-1979)